Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal Menveo and Nimenrix Dose Finding
NCT01782066Phase 2Completed
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2013
- Primary completion
- Feb 2014
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of meningococcal A conjugate vaccine and Meningococcal polysaccharide vaccine group W-135 in meningococcal disease (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Seroprotection rate against meningococcal serogroups ACYW135 at 28 days. Started Jan 2013; status: completed.
02
Drugs
meningococcal A conjugate vaccineMeningococcal polysaccharide vaccine group W-135
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT01782066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01782066.